Manuel Hernández Guerra-rekin lankidetzan egindako argitalpenak (9)

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

2019

  1. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH

    Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676

  2. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain

    PLoS ONE, Vol. 14, Núm. 11

2018

  1. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349

  2. Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))

    Gastroenterologia y Hepatologia

  3. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry

    Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502

2015

  1. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153